Primary effusion lymphoma (PEL) is a rare extranodal lymphoma that typically presents in a body cavity in the absence of a detectable tumor mass and that occurs predominantly in immunosuppressed individuals. e neoplastic lymphoid cells are frequently infected with human herpes virus 8 (HHV8), also known as Kaposi sarcoma herpes virus (KSHV). We describe two HIV-negative patients who presented with primary effusion lymphoma of B-cell lineage involving the pleural cavity, but whose tumor cells lacked infection by HHV8. We review the English language literature of HHV8-negative PEL of B-cell lineage and compare these lymphomas to HHV8-associated PEL with regard to clinical and pathological characteristics, therapy, and outcome.
Introduction
Primary effusion lymphoma (PEL) is a rare extranodal lymphoma of large B cells with characteristic clinicopathologic features including: initial presentation as a body cavity lymphomatous effusion in the absence of a detectable tumor mass; occurrence mostly in human immunode�ciency virus (HIV)-positive individuals; and expression of antigens associated with a late stage of B-cell differentiation, such as CD138 and MUM1/IRF4, without pan-B-cell antigen expression [1] . Human herpes virus-8 (HHV8), also known as Kaposi's sarcoma herpes virus (KSHV), is strongly causally related to PEL and its presence has been incorporated as a diagnostic criterion for PEL [2] .
Diffuse large B-cell lymphoma (DLBCL) constitutes approximately 30-40% of all non-Hodgkin's lymphoma (NHL) and typically presents with a rapidly enlarging symptomatic mass, usually due to nodal enlargement. Extranodal disease with involvement of tissue other than lymph node, spleen, Waldeyer's ring or thymus is quite common in DLBCL, as is secondary involvement of a body cavity by DLBCL [3] . However, primary presentation of DLBCL as a body cavity lymphomatous effusion without any detectable solid mass, similar to HHV8-associated PEL, is extremely rare. Reports of such cases of HHV8-negative PEL of Bcell lineage are limited to isolated case reports and small series. We report two additional cases of this aggressive extranodal lymphoma that presented as a solitary pleural effusion without other sites of disease at the time of diagnosis. In addition, we perform a comprehensive literature review of similar cases with the aim of further characterizing this unusual lymphoma subtype.
Case 1.
An 87-year-old HIV-negative Portuguese female with a past medical history of heart failure with preserved ejection fraction (EF = 60%), hypertension, atrial �brillation, dyslipidemia, and degenerative joint disease was admitted with progressive shortness of breath of two weeks' duration. Complete blood count on admission revealed WBC count of 9600/ L, hemoglobin of 13.7 g/dL, hematocrit of 42.0%, and platelet count of 160,000/ L. Serum total protein and LDH were 6.4 g/dL and 184 IU, respectively. e chest X-ray showed an enlarged cardiac silhouette with bilateral pleural effusions. oracocentesis revealed the pleural �uid to be exudative with glucose of 3 mg/dL, protein of 3.5 g/dL, LDH of 1341 U/L and 9600 nucleated cells/ L, of which 5100 were normal-appearing white blood cells (6% neutrophils, 91% lymphocytes, 3% monocytes) and 4500 were malignantappearing cells.
Cytocentrifuge preparation showed the malignant cells to be large lymphoid cells with irregular nuclei and deeply basophilic cytoplasm with prominent vacuoles (Figures 1(a)  and 1(b) ). Flow cytometry of the pleural �uid showed that the large cells were positive for CD45, CD19, CD20, CD22, CD79a, CD38, HLA-DR, and surface IgM, with aberrant expression of the T-cell antigen, CD8, and the myeloid antigen, CD13. ey were negative for surface and cytoplasmic light chains, MPO, TdT and other T-cell antigens (CD2, CD3, CD4, CD7). Immunoperoxidase stains showed that neoplastic cells were positive for CD45 ( Figure  1(c) ), CD20 (Figure 1(d) ), CD79a (Figure 1(e) ), bcl-2, bcl-6 (>50%), Ki-67 (>90%), epithelial membrane antigen (<50%) and negative for CD10, CD30 and CD138 (Figure 1(f) ). Immunohistochemical staining for HHV8 latency associated nuclear antigen (LANA)-1 and in-situ hybridization (ISH) for Epstein-Barr virus (EBV) were negative. e patient was diagnosed with DLBCL. Further staging to exclude a primary extra-cavitary site of involvement was performed; however, no mass, organomegaly or lymphadenopathy was detected on computed tomography (CT) scans of the chest, abdomen or pelvis. Ultimately, it was felt that a diagnosis of HHV8-negative PEL was most appropriate. e patient was treated only with talc pleurodesis as she declined chemotherapy and radiotherapy. She is alive approximately 24 months aer the procedure and a total of 29 months aer her initial presentation of bilateral pleural effusions.
Case 2.
An 82-year-old HIV-negative Caucasian female with a past medical history of hypertension, sick sinus syndrome, abdominal aortic aneurysm and chronic obstructive pulmonary disease was admitted with dyspnea. Ten years earlier, she was diagnosed with non-small cell lung cancer that was treated with concurrent neoadjuvant chemotherapy and radiation followed by lobectomy. She had no interval clinical or imaging evidence of recurrence of her thoracic malignancy. Chest radiograph during the admission showed a right-sided pleural effusion. oracocentesis revealed malignant cells in the pleural �uid that were large lymphoid cells with irregular nuclear contours, basophilic cytoplasm and multiple nucleoli (Figures 2(a) and 2(b) ). Immunohistochemical stains showed the neoplastic cells to be positive for CD20 (Figure 2(c) ), PAX5/BSAP, bcl-6, MUM1/IRF4 (subset) and kappa light chain (Figure 2(d) ), weakly positive for bcl-2, and negative for CD5, CD10, CD15, CD30, CD138, cyclin D1, lambda light chain (Figure 2 pattern [4] . F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT whole body scan for staging did not demonstrate additional sites of disease. e expression of mature B-cell markers and absence of HHV8, EBV, CD30 and CD138 expression excluded the diagnosis of HHV8-associated PEL and the patient was given the diagnosis of HHV8-negative PEL.
e patient became symptomatic with dyspnea a month later and chest X-ray showed recurrent pleural effusion. oracocentesis was repeated and examination of the pleural �uid by cytology and �ow cytometry revealed only reactive mesothelial cells and histiocytes, without evidence of malignant-appearing cells (Figure 2(f) ). No clonal Bcell population was detected by concurrent �ow cytometry. Spontaneous regression of lymphoma was re-con�rmed with repeat thoracocentesis a week later yielding no malignant cells. However, follow-up FDG PET/CT whole body scans done 4 months later showed a new FDG-avid pleural-based small nodule and various nodularities in the omentum. Tissue biopsy of these nodules was not attempted, but they were believed to be consistent with metastatic progression of the lymphoma. e patient refused any chemotherapy and died 11 months aer her diagnosis of lymphoma.
Design and Methods
"Primary effusion lymphoma" and "body cavity based lymphoma" were used as search terms to identify Englishlanguage articles from PubMed published in the past 15 years (January 1997 to June 2012). Primary effusion lymphoma was de�ned by the presence of malignant lymphoma cells exclusively in a body cavity or cavities without any contiguous or non-contiguous tumor mass or lymph node enlargement at the time of presentation. e review was restricted to reports of primary effusion lymphomas that were negative for HHV8 and that showed expression of mature pan-B-cell antigens. Editorials, reviews without additional cases, and non-published abstracts were excluded.
Clinical information abstracted for each case included: age at presentation; sex; HIV status by enzyme-linked immunosorbent assay (ELISA) or Western blot studies; detection of hepatitis C virus (HCV) by serologic studies or polymerase chain reaction (PCR); detection of EBV by PCR; site(s) of disease; therapy; and outcome. Pathological data collected for each case included: lymphoma cell morphology and immunophenotype; HHV8 LANA-1 expression by immunohistochemistry or detection of HHV8 by PCR or ISH; detection of EBV by EBV latent membrane protein-1 (LMP1) expression or EBER ISH; and results of IGH@ gene rearrangement and cytogenetic studies.
Results
e preliminary search for reports using the above mentioned terms yielded 1187 articles. Aer excluding reports of HHV8-associated PEL and cases of T-cell or null immunophenotype, we identi�ed 34 articles describing 46 unique cases . Our review includes these 46 cases and our 2 cases for a total of 48 reported cases of HHV8-negative PEL. Clinical characteristics are summarized in Table 1 and detailed clinical and pathological �ndings in each case are listed in Table 2 . e 48 patients had a median age at diagnosis of 74 years (range: 14-99 years) with a male-to-female ratio of 3 : 2. Information regarding HIV status was available in 41 patients, and none were reported to be HIV-positive. e association with HCV and EBV infection was found to be 22.2% and 21.3%, respectively. For the 41 patients with information available regarding site of disease, the frequencies of various sites of involvement were as follows: pleura: 65.9%, peritoneum: 39.0%, and pericardium: 36.6%. A single case (case 48) involved the scrotum.
Most cases consisted of medium-sized to large or largesized cells that were occasionally described as pleomorphic.
All cases expressed one or more pan-B-cell antigens (CD19, CD20 and/or CD79a) and several cases expressed surface and/or cytoplasmic immunoglobulin, antigens typically absent in HHV8-associated PEL [16] . e immunophenotype was variable with regard to germinal center (CD10, bcl-6) and post-germinal center (MUM1/IRF4) markers, but no case was reported to express CD138, a plasmacytic antigen typically seen in HHV8-associated PEL. Expression of T-cell antigens, a feature reported in occasional cases of HHV8-associated PEL, was seen in only rare cases (two cases with CD5 co-expression [22, 23] and case 1 reported above with CD8 co-expression). At least some cytogenetic information (FISH and/or karyotype) was available in 26 cases. Of these, 12 cases showed a rearrangement or ampli�cation involving MYC at 8q24 and 13 were reported to harbor a complex karyotype, although full karyotypic information was available in only a small number of cases.
irty patients (62.5%) received chemotherapy with a variety of regimens, including cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) in 11 patients; CHOP with rituximab (R) in 3 patients; THP-CVP (pirarubicin, cyclophosphamide, vincristine, prednisolone) in 6 patients; THP-CVP + R in 4 patients; and other chemotherapy regimens in 6 patients. Treatment was unknown in 1 patient. e remaining 17 patients (35.4%) received no chemotherapy and were treated with �uid drainage alone or �uid drainage and pleurodesis. e median overall survival (OS) was 11 months. e number of patients alive at 6 months and 1 year following symptomatic presentation was 77.8% and 61.1% respectively. Patients who received no chemotherapy had a median OS of 8 months (range: 1 week to 80 months) versus 12 months (range: 18 days to 38 months) in patients who received any kind of chemotherapy. e rate of death with any kind of chemotherapy at 6 months was 20% and at 1 year was 33%, compared to 25% and 42% without any chemotherapy. Among the 22 patients who died of their lymphoma, the median OS was 7 months (range: 1 week to 80 months). e median follow-up period in 24 living patients was approximately 14.5 months (range: 2 months to 55 months).
Discussion
Body cavity-based lymphomas are a heterogeneous group of rare non-Hodgkin's lymphomas that arise primarily in the serous body cavities and that result in recurrent effusions. is group includes pyothorax-associated lymphoma and PEL. Pyothorax-associated lymphoma presents as a solid mass localized in the thoracic cavity that is contiguous with the effusion; it is EBV-associated and arises in the setting of long-standing pyothorax resulting from iatrogenic pneumothorax used to treat tuberculosis [38] . In contrast, PEL is typically con�ned to a body cavity and grows in a liquid phase, without any detectable nodal or extranodal mass elsewhere in the body. As illustrated in Figure 3 Tissues [2] , and HHV8-negative PEL, of which the majority (∼80% of cases) express mature pan-B-cell antigens [39] . As only rare cases of HHV8-negative PEL with neoplastic cells of T-cell derivation [40] [41] [42] [43] [44] or null/indeterminate immunophenotype [22, 45, 46] have been reported, we restricted our review to HHV8-negative PEL of B-cell lineage. Our report of two cases and review of the literature demonstrates that these neoplasms are heterogenous, but share common features that distinguish them from HHV8-associated PEL with regard to pathogenesis, clinical characteristics, immunophenotype and prognosis.
While none of the 48 patients with HHV8-negative PEL were HIV-positive, EBV infection was seen in 21.3% of cases, suggesting that altered immunosurveillance may play a pathogenetic role in some cases. Among the 10 EBVpositive cases, all patients were >50 years old, 2 patients had idiopathic CD4+ T-cell lymphopenia and 1 patient had a history of common variable immunode�ciency, supporting this hypothesis [47] . Similarly, 22.2% of patients had underlying HCV infection. HCV has been shown to be lymphotropic and has been implicated as an etiological factor in lymphomagenesis for various NHL subtypes [48, 49] .
Ascoli et al. detected HCV RNA in the ascitic �uid of a patient with HHV8-negative PEL and proposed that HCV may play a causative role in these lymphomas by chronic stimulation of B cells followed by clonal expansion [16] .
In our review, a number of cases were negative for both EBV and HCV (19/48; 39.6%), suggesting that other etiologies also play a role in lymphomagenesis. Among cases with available cytogenetic information, 50% (12/26) harbored ampli�cation or rearrangement of the MYC oncogene, a likely driver of neoplasia in these cases. In terms of Bcell NHL subclassi�cation, most MYC-rearranged cases had large cell morphology or a complex karyotype, consistent with DLBCL [14, 19, 22, 23, 26, 31, 50] Two cases (cases 17 and 18) reportedly had monomorphic medium-sized cells, a germinal center immunophenotype (expression of CD10), and a relatively simple background karyotype, suggesting that these cases may represent an unusual extranodal presentation of Burkitt's lymphoma [16, 17] .
Unlike HHV8-associated PEL, HHV8-negative PEL of B-cell lineage shares several clinical features with nodal or extranodal DLBCL presenting with a mass lesion, and differentiating HHV8-negative PEL from conventional DLBCL complicated by secondary lymphomatous effusion requires a thorough staging evaluation to exclude the presence of a mass lesion at the time of diagnosis. Based on our literature review, HHV8-negative PEL presents at an older median age (74 years) compared to that reported for HHV8-associated PEL (44 years) and exhibits a lower male-to-female ratio, similar to DLBCL [2, 44, 51, 52] . e overall favorable prognosis compared to HHV8-associated PEL was underscored by a survival rate of approximately 60% at 1 year and a median OS of 11 months. While this compares favorably to HHV8-associated PEL with a reported median OS of 4-6 months [2, 44] , the range was quite wide (1 week to 80 months). is heterogeneity in clinical behavior is further highlighted by our �nding of a small number of patients who presented with involvement limited to a single body cavity site, but who developed mass lesions outside of the body cavity at the time of disease progression, similar to our case 2 [32] . At the other extreme, our case 1 showed regression of the malignancy aer pleurodesis and drainage of the pleural �uid without any chemotherapy, and in our literature review we identi�ed 7 other patients in whom the lymphoma similarly regressed following drainage of the effusion [5-7, 12, 18, 23] .
ere is no clear consensus on the appropriate treatment of HHV8-negative PEL due to the limited number of cases reported. Our �ndings suggest that chemotherapy bene�ts most patients, as those treated with any type of chemotherapy overall had a lower rate of death compared to patients who received no chemotherapy. Remarkably, the addition of rituximab to chemotherapy regimens induced remission in all 8 patients, 7 of whom were alive at the time of last follow-up [4, 8, 12, 13, 29, 31, 32] . e single patient who died following a rituximab-containing regimen died prematurely of a cause unrelated to lymphoma [8] . erefore, treatment with drainage of the effusion followed by chemoimmunotherapy with rituximab and CHOP, particularly in CD20-positive cases, appears to offer the possibility of prolonged survival in a subset of patients. Further study of rare patients who undergo spontaneous regression of their lymphoma following drainage alone may help to identify clinical or pathological features that predict for a good outcome following only minimal therapy.
